The current notion is that CpG-ODNs augment specific immune responses through TLR9 mediated NF-κB activation, as well as CpG-ODN itself exhibits anti-tumour activity via reduction of VEGF and HIF-1α38. The gene discussed is NFKB1; the disease is neoplasm.